The leading global voice
We play a major role in bringing the CV community together to drive transformational change.
Together we are stronger
By 2025, our aim is to reduce premature deaths from CVD by at least 25%.
Join the fight
Become a WHF member and help us to build global commitment to address cardiovascular health at the policy level.
We convene and connect our members
To share science, best practice and resources, acting as a global thought leader and catalyst for positive change.
Celebrate World Heart Day
The biggest global awareness-raising campaign for CVD.
Attend the Congress
Join world leaders in heart health, share ideas, network with specialists.
Advocating for heart health
We lead the global advocacy effort for action to prevent, control and reduce the global burden of CVD.
All our programmes and partnerships are aimed at creating awareness of CVD as a priority issue across the globe.
Find out more about our and our members' work around the world.
Explore everything from toolkits, videos and infographics, to policy reports, factsheets and more.
The latest issue of the Journal of the American College of Cardiology, features an article entitled Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases, which is co-authored by two Emerging Leaders, Sandeep Kishore and Rajesh Vedanthan, as well as Emerging Leaders Senior Program Advisor and Associate Professor of Epidemiology and Cardiology at Northwestern University, Mark Huffman. You can read the abstract below.
Rajesh Vedanthan is a member of the 2014 cohort with the WikiMeds group project, which aims to evaluate the acceptability and feasibility of WikiMeds as a strategy for addressing known barriers to the use of secondary prevention medications using qualitative research methods, and to iteratively and contextually adapt and refine the WikiMeds platform based on the results of the first aim.
Sandeep Kishore is member of the 2017 cohort, which focused on essential medicines.
The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts.
3rd Global Summit on Circulatory Health held in Dubai
40 Years of the World Heart Federation
WHF RHD Taskforce meets in Dubai